Tanya Dorff, MD Genitourinary Cancers:Evolving Practices and Controversies @MOASC_Office @cityofhope

Tanya Dorff, MD Genitourinary Cancers:Evolving Practices and Controversies @MOASC_Office @cityofhope

User Photo
moasc

7 months
67 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:

Tanya Dorff, MD Associate Clinical Professor of MedicineHead of Genitourinary Cancer Program City of Hope discusses Genitourinary Cancers:Evolving Practices and Controversies, STAMPEDE: (Docetaxel) in mHSPC, LATITUDE Trial, docetaxel, ENZAMET, SWOG S1802, TITAN, mCRPC, Cabazitaxel, Enzalutamide, Radium223, Sipuleucel-T, Docetaxel (TAX), ADT, A031201, EORTC 1333 / PEACE III2, PARP inhibitors, TOPARP- B, niraparib, rucaparib, talazoparib, PHASE III PROFOUND, Pembrolizumab, KEYNOTE-991, 177-Lu PSMA, VISION trial, CAR-T, BiTE antibody, Erdafitinib, FGFR TKI, Enfortumab, EV 302, Docetaxel, Vofatamab, nivoluamb and more at the MOASC Summit 2020

Sponsors:

AbbVie 

AMAG

AstraZeneca 

Bayer 

BeiGene 

Clovis Oncology

Coherus 

Daiichi-Sankyo 

Dova Pharmaceuticals 

Foundation Medicine 

Jazz Pharmaceuticals  

Merck 

Pfizer Oncology 

Puma Biotechnology 

Tempus 

Verastem oncology

Walgreens 

Up Next Autoplay
>